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Abstract : Dengue virus is a member of flavivirus group. Diseases caused by flaviviruses
have been a scourge of mankind for long history of human kind; with yellow fever at the top,
followed by dengue fever, Japanese encephalitis (JE) and Russian spring-summerencephalitis
(RSSE). Due to the dvevelopment of a safe and efficacious live-attenuated vaccine against
yellow fever as a first laboratory-designed virus vaccine, this disease is no longer a threat in
countries where adequate vaccination is practiced. Similarly, safe and efficacious inactivat-
ed vaccines against JE and tick-borne encephalitis (TBE) have also been developed, resulting
in dramatical reduction in the disease incidences. In spite of these successes, the development
of vaccines against other pathogenic flaviviruses, such as dengue fever and RSSE have not
been successful. Control of dengue virus became rather urgent because of the emergence of
newsyndrome, dengue hemorrhagic fever (DHF), which causes high mortality amonginfants.
The present review attempts to summarize the characteristics of dengue fever and DHF,
commonfeatures of flavivirus infections as the basis vaccine development and recent
advances and problems encountered in dengue vaccine research.
1. Diseases Caused by Flaviviruses.
Diseases caused by flaviviruses have been recognized as severe public health prob-
lems in various parts of the world for centuries. Yellow fever was first identified in 1667
in Barbados and continued to be a major threat to public health in the Americas throughout
the nineteenth and the early part of the twentieth century. In Africa, yellow fever has still
been causing periodic epidemics with the most recent occurring in Gambia and Ghana in
1978. Dengue fever has been recognized since 1780 and has since been described in every
continent including Europe and Americas. Dengue fever continues to be a serious threat
with outbreaks occurring almost annually in south-east Asia, causing several hundred
deaths, particularly of young children. A severe, occasionally fatal form of the disease
was reconized in Asia in 1957. This new type of dengue infection, called DHF, has since
been recognized in Caribbean during the 1970's, and in 1981, a large outbreak occurred in
Cuba. There is a hypothesis that DHF has an immunopathological basis and occurrs in
individuals previously sensitized by infection with a heterologous dengue serotype1'.
JE became a serious public problem in the mid 1930 in Japan and recently finding
further dissemination among south and south-east Asian countries like India and Thailand.
328
b een developed by incorporating the recombinant DNA technology. A dengue 4
baculaovirus recombinant expressed both E and NS1 proteins in insect cell host, and the
protein products induced protective immunity in mice13). Purified NS1 protein from
dengue-infected cells was also shown to induce protective immunity in mice14). This new
approach to immunization without involvement of virion antigen, which is related to the
induction of enhancing antibodies, may be of great theroretical importance, in special
referenc to the control of DHF. Recombinant vaccinia virus expressing dengue 4 struc-
tural and non-structural proteins were also active in immunizing mice against the same
type of dengue virus15). The most possible combination of dengue virus immunogenseems
to be E+NS1 in serotypes so far tested. WHO is coordinating a collective efforts of
flavivirus experts to develop the dengue vaccine based on 4 approaches : a. identification
of protection-inducing antigen or determinant, b. development of most effective expression
system of that antigen, c. identification of pathogenicity gene, and d. development of
artifically produced attenuated virus, including the recombinant virus16).
4. Problems to be Considered in the Dengue Vaccine Development.
The ability of specific antibodies to enhance the replication of viruses in cell culture
system has been described for a variety of cells and viruses. Most work on this phenome-
non of antibody-dependent enhancement (ADE) has been performed in macrophages or
macrophage cell lines. The mechanism of ADE in vitro has been elucidated, i. e. IgG
antibody molecules bind to virus particles and the virus-antibody complex can then bind to
the Fc receptor on the macrophage (or any Fc receptor-bearing cell). Thus virus particles
which normally cannot infect these cells are able to use the Fc receptor as a virus receptor.
Another mechanism utilizing the binding of virus-IgM complexes to the C3 receptor was
also reported with flavivirus17).
The serious role of ADE has been demonstrated in humans infected with dengue
virus. Early observations of children with the more severe forms of dengue virus infec-
tion, i. e. dengue hemorrhagic fever or dengue shock syndrome (DHF/DSS), indicated that
children with antibodies to one serotype (either from a previous infection or from maternal
antibody) had an increased risk of contracting DHF/DSS when an epidemic involving
another serotype appeared. Antibodies induced by virus of one serotype would bind to
virus of another serotype (as they are antigenically related), but as these antibodies cannot
neutralize the new virus, it will be able to bind to and infect macrophages and thus destroy
a crucial component of the immune system. This hypothesis has been supported by a
series of animal experiments", but its impacts on the grand design of vaccines preventing
dengue fever and DHF have not yet been elucidated quantitatively.
As all flaviviruses contain cross-reacting epitopes on their major envelope glyco-
protein (E), it is possible that vaccination against one virus may enhance the infection with
another, or even worse change a non-virulent vaccine strain into a virulent virus. So far,
the possibilities were not materialized, in fact, the opposite effect has been observed
between different flaviviruses. Previous vaccination of human volunteers with yellow
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relationships among subtypes and other flavivirus members are being revealed by the
introduction of monoclonal antibody method, e. g. between dengue 2 and 4 and between
dengue and JE and TBE complex viruses. Geographic distribution of 14 variants of
dengue 2 virus differentiated by monoclonal radio-immunoassay (RIA) correlated clearly
with the genomic variation demonstrated by RNA oligonucleotide fingerprinting6).
In spite of the world-wide prevalence of dengue fever, the development of vaccines
against this virus have not been successful. The only vaccines available against dengue
fever at present are for serotypes 1 and 2 and all of these are still to be called the
experimental vaccines. Further, there is no record of any inactivated vaccines being
developed, principally because all dengue serotypes grow poorly in cultured cells.
The first vaccine against dengue type 1 was proposed by Sabin's group. This was
a live attenuated vaccine derived by repeated passage of the Hawaian isolate in mouse
brain and was shown to be protective in human volunteers7). A similar vaccine against
dengue 2 was later developed from the New Guinea B isolate by a similar procedure and
produced a good serological response in human volunteers. Similar vaccines were prepar-
ed by adaptation to avian fibroblast culture with similar limited success to mouse brain
vaccines. Despite earlier promising results, works on these vaccines were discontinued
due either to limited immunogenicity or to relatively high frequency of adverse effects.
Recent successful studies with dengue vaccines have been based upon a small-
plaque, temperature-sensitive (ts) clone, PR-159/S1, derived from a dengue-2 virus isolated
in Puerto Rico from a patient of dengue fever. The virus was shown to be attenuated for
humans, but caused limited adverse reactions with fever, rash and leukopenia in some
recipients*0. Double-blind, placebo-controlled trials in human volunteers revealed that
this vaccine caused slightest vaccine-related symptomes in some individuals. An interest-
ing feature of this vaccine was that seroconversion, as measured by the development of
neutralizing antibody was as low as 61% in nonimmune volunteers, whereas individuals
who has record of^previous vaccination against yellow fever gave seroconversion rates of
90%9). The synergistic effect of flavivirus vaccinations was confirmed by several workers
and may pose double-edged considerations in both benefitial and adverse directions.
One of the most promising candidate dengue 2 vaccines has been developed recently
by a group in Thailand using a human isolate in Thailand (16681) adapted to growth in
primary canine kidney cell cultures10'. The virus strain 16681-PDK53 demonstrated many
in vitro markers for attenuation and protected human volunteers without the adverse
effect seen in earlier vaccines. The vaccine was immunogenic even in individuals without
other flavivirus immunity. These workers also report that a similar vaccine to other
serotypes being developed in their laboratory, and a tetravalent vaccine composed of Den
-l-PDK-13, Den-2-PDK-53, Den-4-PDK-48, and Den-3-PGMK-30 (passaged through
primary African green monkey kidney cells), was reported to be safe and immunogenic
with minimal febrile reaction and good antibody response in both adults and infantsll'.
An experimental vaccine against dengue 4 has been described by an American
team12), details of the efficacy and safety seem yet to be seen. Various strategies have also
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St. Louis encephalitis first became a serious public health problem in the continental USA
in 1960s and sporadic outbreak continues to be a cause of concern.
The tick-borne flaviviruses, like their mosquito-borne counterparts, are amongst
the earliest known causes of infectious diseases. Ovine encephalomyelitis (louping ill)
amongsheeps and RSSE were described in the nineteenth century. TBE was first recog-
nized in 1930's in central Russia and far-eastern subtype of TBE virus continues to be a
major public health problem in eastern Russia with a high mortality rate and frequent long
-lasting neurological lesions. The western subtype of TBE, prevalent in east and central
Europe, is closely related to louping ill, but with less severe clinical symptoms and much
lower mortality rate. Apart from TBE, there are relatively few tick-borne flaviviruses ;
the most important are Omsk hemorrhagic fever of central Russia and Kyasanur forest
disease of India.
2. Structure and Replication of Flaviviruses.
The flaviviruses have the structure of enveloped, spherical nucleocapsid, with
unknown symmetry, of the size 40-50 nm in diameter. The genome consists of one
molecule of positive-sense, infectious single strand RNA, size 10 kb. The viruses have
three major structural polypeptides2), one of which is glycosylated. Genomesequence has
been elucidated on several mosquito-borne viruses311 but very little data are available on the
tick-borne flaviviruses. The sequence data suggest that there are ten virus-specified
proteins and this is in close agreement with what is found in cells infected with mosquito
-borne and tick-borne viruses.
The minor component of the envelope is a small non-glycosylated polypeptide (M)
which is sometimes found in virion particles as a glycosylated precursor, pre-M. The
major protein of the virus envelope (E) is present as an oligomeric complex and contains
all the observable biological properties associated with the virus particle, i. e. antibodies
directed against epitopes on the E polypeptide are responsible for plaque-reduction neutral-
ization, hemagglutination inhibition, passive protection, complement-fixation and antibody
-dependent enhancement. Sera from animals infected with flaviviruses or vaccinated
against them contain antibodies to a non-structural glycoprotein NS1. The precise
functions in virus infection or immunity of non-structural proteins, NS1, NS2a, NS2b, NS3,
NS4a, NS4b and NS5 are unknown at present, although some or them are suggested to be
involved in RNA replication.
The genome structure of the flavivirus is very similar to that of the picorna-viruses,
and their protein synthesis strategies are expected to be very similar. But there has been
little evidence indicating the presence of precursor molecules in favivirus-infected cells.
3. Vaccines against Dengue Virus.
Four serotypes (types 1-4) are recognized on the basis of plaque reduction neutraliza-
tion tests4), and constitute a distinct antigenic complex. Dengue types 1 and 3 form a
subcomplex defined by monoclonal and polyclonal antibodies5). Additional antigenic
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fever vaccine increased the seroconverion rate of an experimental dengue-2 vaccine and a
similar synergistic effect was observed between yellow fever vaccination and TBE vac-
cines. Although ADE does not appear to be the problem with flavivirus vaccines at
present, dengue vaccine should be developed with special vigilance in this respect.
Flaviviruses are characteristic in that the major virion structural protein E may not
be present on the surface of the infected cell, but non-structural protein NS1 is. It implies
that if a vaccine contains only components from E, free virus particles will be eliminated,
but infected, virus-producing cells would not be. In the similar case of inactivated measles
vaccine, the consequences were tragical. The converse situation could be feasible if a
vaccine contained only components from NS1. In this case, infected cells may be killed
but virus which had escaped would be free to travel throughout the host and infect other
tissues. It is therefore essential to ensure that new component vaccines against flavivir-
uses should contain components from both E and NS1 proteins.
5. Conclusion.
Although ADE is a theoretical concern in developing the flavivirus vaccine, there has
been no evidence that it is a problem with flavivirus vaccines so far developed. But, as the
pathogenesis of DHF strongly suggests the involvement of ADE, development of any
dengue vaccine should maintain the vigilance against this mechanism. Development of
animal model reproducing human DHF should be given the top priority from this point of
view. After establishing the pathogenic mechanism of DHF, programmed vaccines
containing protein components maynot be difficult. Development of artificial attenuated
live vaccine may be feasible after the elucidation of gene product(s) involved in the genesis
of DHF. Recombinant or chimeric viruses may be possible to be constructed by advanced
recombinant DNA technology.
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